Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Trial details
- Registry ID
- NCT02873338
- Phase
- Phase 2
The FDA approved Idarubicin (Idamycin) on 27 Sep 1990.
Drug identity checked against registry records
Also recorded as Idamycin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaNCT02873338 | Jazz Pharmaceuticals | Phase 2 | Completed | 2019-06Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1990-09-27Day | Idarubicin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA050661", "applicant_as_listed_by_fda": "PFIZER", "brand_names": ["IDAMYCIN"], "active_ingredients": ["IDARUBICIN HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19900927", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |